Results for Niraparib Maintenance Therapy for Patients With Ovarian Cancer

March 14, 2017
Ursula A. Matulonis, MD

Ursula A. Matulonis, MD, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo.